SG Americas Securities LLC Sells 76,236 Shares of Arvinas, Inc. (NASDAQ:ARVN)

SG Americas Securities LLC cut its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 88.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,860 shares of the company’s stock after selling 76,236 shares during the period. SG Americas Securities LLC’s holdings in Arvinas were worth $243,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Arvinas by 29.9% in the 1st quarter. Vanguard Group Inc. now owns 6,299,556 shares of the company’s stock worth $260,046,000 after acquiring an additional 1,448,166 shares in the last quarter. Swiss National Bank raised its position in shares of Arvinas by 27.5% in the 1st quarter. Swiss National Bank now owns 114,100 shares of the company’s stock worth $4,710,000 after acquiring an additional 24,600 shares in the last quarter. Los Angeles Capital Management LLC raised its position in shares of Arvinas by 7.1% in the 1st quarter. Los Angeles Capital Management LLC now owns 29,882 shares of the company’s stock worth $1,234,000 after acquiring an additional 1,993 shares in the last quarter. Candriam S.C.A. raised its position in shares of Arvinas by 32.0% in the 2nd quarter. Candriam S.C.A. now owns 610,458 shares of the company’s stock worth $16,250,000 after acquiring an additional 147,904 shares in the last quarter. Finally, Magnetar Financial LLC raised its position in shares of Arvinas by 112.7% in the 2nd quarter. Magnetar Financial LLC now owns 41,992 shares of the company’s stock worth $1,118,000 after acquiring an additional 22,245 shares in the last quarter. 95.19% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ARVN shares. HC Wainwright restated a “buy” rating and issued a $87.00 target price on shares of Arvinas in a research note on Thursday, August 1st. Barclays reduced their target price on Arvinas from $60.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. Wedbush restated an “outperform” rating and issued a $57.00 target price on shares of Arvinas in a research note on Tuesday, July 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research note on Monday, September 9th. Finally, Oppenheimer reduced their target price on Arvinas from $70.00 to $50.00 and set an “outperform” rating for the company in a research note on Wednesday, July 31st. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Arvinas Stock Down 5.0 %

Shares of NASDAQ ARVN opened at $25.76 on Tuesday. Arvinas, Inc. has a twelve month low of $13.57 and a twelve month high of $53.08. The stock’s 50 day moving average price is $25.30 and its 200-day moving average price is $28.30. The company has a market capitalization of $1.76 billion, a PE ratio of -4.34 and a beta of 1.97.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, July 30th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.59. The business had revenue of $76.50 million during the quarter, compared to analysts’ expectations of $33.27 million. During the same quarter in the previous year, the firm earned ($1.25) EPS. Arvinas’s quarterly revenue was up 40.4% on a year-over-year basis. As a group, research analysts expect that Arvinas, Inc. will post -3.51 EPS for the current fiscal year.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.